Literature DB >> 21432392

Pleiotrophic actions of erythropoietin.

Laurie Feldman1, Arthur J Sytkowski.   

Abstract

Erythropoietin is the prime regulator of red blood cell production. However, recent evidence suggests that the hormone has multiple effects outside the hematopoietic system. Functional receptors have been identified on a wide variety of normal and malignant cell types, and numerous biologic effects of the hormone on these cells have been observed both in vitro and in vivo. These findings are causing a reassessment of the understanding of erythropoietin physiology. Moreover, there are important implications for the use of recombinant erythropoietin in the clinical setting.

Entities:  

Keywords:  angiogenesis; brain; cancer; gut; reproductive system

Year:  2003        PMID: 21432392      PMCID: PMC2723462          DOI: 10.1007/BF02908882

Source DB:  PubMed          Journal:  Environ Health Prev Med        ISSN: 1342-078X            Impact factor:   3.674


  72 in total

Review 1.  Hematopoiesis and angiogenesis: a link between two apparently independent processes.

Authors:  D Ribatti; A Vacca; L Roncali; F Dammacco
Journal:  J Hematother Stem Cell Res       Date:  2000-02

Review 2.  The hemangioblast: a common progenitor of hematopoietic and endothelial cells.

Authors:  Kyunghee Choi
Journal:  J Hematother Stem Cell Res       Date:  2002-02

3.  Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation.

Authors:  G Calapai; M C Marciano; F Corica; A Allegra; A Parisi; N Frisina; A P Caputi; M Buemi
Journal:  Eur J Pharmacol       Date:  2000-08-11       Impact factor: 4.432

Review 4.  Human hematopoietic growth factors: old lessons and new perspectives.

Authors:  W Dempke; A Von Poblozki; A Grothey; H J Schmoll
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

5.  Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.

Authors:  U Bunworasate; H Arnouk; H Minderman; K L O'Loughlin; S N Sait; M Barcos; C C Stewart; M R Baer
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

6.  Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.

Authors:  M Mittelman; D Neumann; A Peled; P Kanter; N Haran-Ghera
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

7.  Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers.

Authors:  J Dunst; P Stadler; A Becker; T Kuhnt; C Lautenschläger; M Molls; G Haensgen
Journal:  Strahlenther Onkol       Date:  2001-09       Impact factor: 3.621

Review 8.  The impact of hemoglobin levels on treatment outcomes in patients with cancer.

Authors:  T J Littlewood
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

9.  Erythropoietin acts as a trophic factor in neonatal rat intestine.

Authors:  S E Juul; D J Ledbetter; A E Joyce; C Dame; R D Christensen; Y Zhao; V DeMarco
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

10.  Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.

Authors:  A Anagnostou; E S Lee; N Kessimian; R Levinson; M Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

View more
  1 in total

1.  Endothelial nitric oxide synthase mediates the cerebrovascular effects of erythropoietin in traumatic brain injury.

Authors:  Jovany Cruz Navarro; Shibu Pillai; Lucido L Ponce; Mai Van; Jerry Clay Goodman; Claudia S Robertson
Journal:  Front Immunol       Date:  2014-10-09       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.